FreeTheAI

Immutep Regains Nasdaq Compliance Following Ratio Change

NeutralMedium impact
IMMA$0.0260 −3.70%

Immutep Limited (ASX:IMM) has regained compliance with Nasdaq's minimum bid price requirement. The company satisfied the threshold after its American Depositary Shares closed at or above $1 for 10 consecutive business days through October 9, 2026.

The price increase followed an adjustment in the company's ADS ratio from 10:1 to 200:1, effective September 28, 2026. This share consolidation mechanically raised the per-share bid price, prompting Nasdaq to officially close the matter. Resolving the issue removes delisting risk and the associated pressure on liquidity.

While the mechanical change satisfied listing standards, sustainable valuation growth will require operational progress. Investors will look to future clinical and regulatory milestones to drive long-term momentum.

Key points

  • Immutep Limited (ASX:IMM) regained Nasdaq minimum bid price compliance after its shares closed at or above $1 for 10 consecutive business days.
  • The compliance requirement was met through October 9, 2026, satisfying Nasdaq Rule 5450(a)(1).
  • Per-share prices were boosted mechanically by an ADS ratio change from 10:1 to 200:1 effective September 28, 2026.
  • Nasdaq has formally closed the matter, eliminating delisting risks for the company.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Immutep need to regain Nasdaq compliance?

Immutep needed to meet Nasdaq minimum bid price rules after its shares fell below the $1 threshold.

How did Immutep satisfy the Nasdaq $1 minimum bid requirement?

Immutep altered its ADS ratio from 10:1 to 200:1 on September 28, 2026, which mechanically lifted the share price above $1 for 10 straight business days through October 9, 2026.

Is Immutep still facing delisting risk from Nasdaq?

No, Nasdaq has officially closed the matter after Immutep met the 10-day requirement, removing immediate delisting risk.